drugset / Trial / NCT00907803
Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246
RandomizedParallel-groupDouble-blind
Summary
The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of two clinical doses of the anti-orthopoxvirus drug, ST-246, administered as a single daily oral dose for 14 days to healthy, fed volunteers. The results of this trial determine which dose will be used in expanded pivotal safety trials.
Timeline
- Start
- 2009-06
- Primary completion
- 2010-01
- Completion
- 2010-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tecovirimat | Small molecule | 400 mg | Oral |
| Subject | Tecovirimat | Small molecule | 600 mg | Oral |